RABIES VACCINE MARKET ANALYSIS (2020-2027)

1

• Coherent Market Insights
• Market Research and Business Consulting Services
• https//www.coherentmarketinsights.com/
• COVID-19 Impact Tracker

2
RABIES VACCINE MARKET ANALYSIS (2020-2027)

• Rabies Vaccine Market Industry Insights,
  Trends, Outlook, and Opportunity Analysis 2020-
  2027

3

• Rabies is a viral zoonotic disease caused through
  a dogs bite which leads to progressive and fatal
  inflammation of the brain and spinal cord. There
  are two type of rabies furious rabies and
  paralytic rabies. Symptoms accompanied with
  furious rabies are hyperactivity and
  hallucination. Paralytic rabies can cause coma
  and paralysis. Rabies seems fatal disease but it
  can be controlled through vaccines and medicines
  which have long been available to prevent death
  by rabies. According World Health Organization
  (WHO), globally rabies cause fatalities nearly
  10,000 people yearly and almost 99 cases are due
  to dog bites. Symptoms caused by rabies are
  wound, fever with pain near the wound, tingling,
  pricking at wound site, and if not treated
  properly it can lead to cardiac or respiratory
  arrest. According to World Health Organization
  (WHO), in 2017, rabies caused 59,000 deaths
  annually in 150 countries with 95 cases in rural
  districts.

4
Global Rabies Vaccines Market- Drivers

• Key players are focused on research and
  development strategies which are expected to
  drive the global rabies vaccine market growth
  during the forecast period. For instance, in
  2017, CPL Laboratories (India), a joint venture
  biotechnology company established in 2009 by
  Novavax Inc., USA and Cadila Pharmaceuticals
  Limited, stated that Nano- particle vaccine of
  baculvirous-derived glycoprotein, a four dose
  regime vaccine is in phase-3 human trial, and is
  expected to be approved by 2021.

5

• In U.S., rabies in early 1960 to 2000 was
  negligible, and witnessed a sudden rise resulting
  in 100 cases annually.  Although the fatalities
  were rare, lack of awareness towards rabies is
  proving to be a risk. From 1960 to 2018, 127
  cases of rabies were reported in U.S. from dog
  bites and bat bites. Whereas in Asia, rabies is a
  major burden, accounting for almost 35,000
  deaths, fatalities caused by rabies in India are
  55.  In Africa, an estimated 21,476 human deaths
  occur due to dog bite rabies, Africa spends less
  on the post exposure prophylaxis treatment of
  rabies and have highest mortality rate due to
  rabies. Central Asia and Middle East Asia have an
  estimated 1875 and 229 fatalities yearly. These
  factors are is expected to drive the global
  rabies vaccines market growth during the forecast
  period.

6
Global Rabies Vaccines Market-Impact of COVID-19
Analysis on the Global Rabies Vaccine Market

• The impact of COVID-19 on the global rabies
  vaccine market has affected every market around
  the globe in a negative way. As the world still
  struggles to recover from the COVID-19 situation
  it will take a long time for every market to
  recover its losses. People have been reluctant to
  visit the physicians for vaccination due to
  social distancing. As per the situation, the
  impact of COVID-19 has strongly affected the
  future market opportunities, revenue growth
  graph, and the profit gains of the business for
  global rabies vaccine market.  

7
Global Rabies Vaccines Market - Restraints

• Emerging economies in Africa and Asia are
  expected to witness a major burden of rabies due
  to lack of awareness and costly treatment. Post
  exposure, prophylaxis is a dose regime for dog
  mediated rabies. According to World Health
  Organization (WHO), in 2017, the estimated cost
  of PEP was US 1.5 million, which can make it
  unaffordable in mid- or low-income countries and
  restrain the growth of the global rabies vaccines
  market during the forecast period.   

8
Global Rabies Vaccine Market Regional Analysis

• Regional segmentation of the global rabies
  vaccine market includes North America, Latin
  America, Europe, Asia Pacific, Middle East, and
  Africa. North America is projected to dominate
  the global rabies vaccines market with the
  largest share during the forecast period. The
  rising investments by governments in the public
  sector, as well as programs to eradicate rabies
  are favouring growth of the market in the region.
  For instance, countries in North America in 2008
  established the North America Rabies Management
  Plan, by assessing and defining the needs,
  priorities to control rabies and eventually
  eliminate it from Canada, Mexico, and the U.S.

9

• According to the European Centre for Disease
  Prevention and Control, in 2014 only 3 cases of
  rabies were reported in Europe, whereas Europe
  being the highest vaccine manufacturer for
  rabies. Key market players in Europe are
  GlaxoSmithKline, SanofiPasteur and Novartis AG.
• Furthermore, the market in Asia Pacific is
  expected to witness significant growth owing to
  active involvement by manufacturers in Asia
  Pacific countries such as China, Japan and India
  regarding development of innovative rabies
  vaccine and its substitutes. In February 2018,
  BioNote, Inc., a South Korean veterinary
  diagnostic company operating in rabies
  diagnostics, announced the launch of a new
  immune-fluorescent device, Vcheck, which can
  measure diagnostic result values with the help of
  fluorescent materials which help in detecting the
  zoonotic disease in animals.

10

• The market in Asia Pacific is expected to witness
  new entrants and is a major competitive market
  due to the burden of rabies. According to data
  published by the World Health Organization (WHO)
  in 2017, India accounts for 59.9 of deaths due
  to rabies in Asia, and 35 of deaths globally.
  Major players operating in the region are Yisheng
  Biopharma, Serum Institute of India, Zuventus,
  and Bharat Biotech Ltd. Moreover companies such
  as Yisheng Laboratories and CPL Laboratories
  (India) have vaccine candidates in clinical
  trials.

11
Global Rabies Vaccine Market- Competitive
Landscape

• Key players operating in global rabies vaccine
  market are Sanofi S.A., Novartis International
  AG, Serum Institute of India Pvt. Ltd, Indian
  Immunologicals Limited, Bharat Biotech Ltd,
  Zuventus HealthCare Ltd., Cpl Biologicals Private
  Limited, Yisheng Biopharma Co., Ltd,
  GlaxoSmithKline plc, Bavarian Nordic A/S, and
  Chiron Behring Vaccines Private Limited.

12
Key Developments-

• In 2016, Serum Institute of India, developed new
  rabies vaccine, RABIVAS-S, for countries with
  highest burden of rabies.
• The World Organization for Animal Health (OIE), a
  vaccine bank, was established in 2012 with
  production order for rabies vaccine of 50,000
  doses in 31st December 2016. The OIE recorded 16
  million doses of vaccines in 24 countries for
  pre- and post-exposure prophylaxis treatment for
  rabies.
• In 2019, Yisheng Biopharma (Singapore) Pte Ltd
  stated that development of adjuvant rabies
  vaccine, PIKA which is composed of RABIPUR and
  polyisonic-polycytidcyclic acid, has completed
  its phase 2 clinical trial.

13

• In 2019, GlaxoSmithKline divested its rabies and
  tick-borne vaccine to Bavarian Nordic, and
  incurred payment of 36 million from Bavarian
  Nordic.
• In 2019, Asian subsidiary of GlaxoSmithKline
  divested its Chiron Behring Vaccines unit in
  Gujarat, India to domestic clinical biotechnology
  company, Bharat Biotech.
• In 2019, Wuhan Institute of Virology announced
  positive results of a novel rabies vaccine in
  pre-clinical test. The novel vaccine is a live
  attenuated vaccine VEEV-RABV-G.
• In June 18, 2020 Bavarian Nordic A/S and Valneva
  SE announced a partnership for marketing and
  distribution of rabies and tick-borne vaccines in
  selected European countries and Canada.

14
Global Rabies Vaccine Market - Taxonomy

• By Vaccine Type-
• In 2016, Serum Institute of India, developed new
  rabies vaccine, RABIVAS-S, for countries with
  highest burden of rabies.
• Neutral vaccine
• Suckling mouse brain vaccine
• Semble rabies vaccine
• Nonneutral vaccine
• Duck embryo vaccine
• Cell culture vaccine

15

• By Vaccine Type-
• Human diploid cell vaccine (HDCV)
• Purified chick embryo cell vaccine (PCECV)
• Purified Vero cell rabies vaccine (PVRV)
• Primary hamster kidney cell vaccine (PHKCV)
• By Route of Administration-
• Intra-muscular vaccine
• Oral vaccine (Veterinary use)

16

• By End User-
• Hospitals
• Clinics
• Vaccination Centres
• By Region-
• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa

17

• Request Sample Report
• Request Customization
• Download PDF Brochure
• Talk to Analyst
• Buy Now
• Referencehttps//www.coherentmarketinsights.com/o
  ngoing-insight/rabies-vaccine-market-4005

18
About Us

• Coherent Market Insights is a global market
  intelligence and consulting organization focused
  on assisting our plethora of clients achieve
  transformational growth by helping them make
  critical business decisions.
• What we provide
• Customized Market Research Services
• Industry Analysis Services
• Business Consulting Services
• Market Intelligence Services
• Long term Engagement Model
• Country Specific Analysis

19
Contact Us

• Mr. Shah
• Coherent Market Insights Pvt.Ltd.
• Address 1001 4th Ave, 3200 Seattle, WA 98154,
  U.S.
• Phone [phone]
• Email sales_at_coherentmarketinsights.com

20

• Thank You!
• Kindly follow CMI Social Media
  Profiles for the latest company updates
• Facebook
• Linkedin
• Twitter
• https//www.coherentmarketinsights.com/